

## Case Report

# Partially Resolving Myocardial Fibrosis Five Months Following the mRNA COVID-19 Vaccine: An MRI Based Case Report

Ashik Imran, Won Jun Park and Michael R. Sood\*

Icahn School of Medicine at Mount Sinai, Mount Sinai South Nassau, Oceanside, NY 11571, USA

\*Address for Correspondence: Michael R. Sood, Icahn School of Medicine at Mount Sinai, Mount Sinai South Nassau, Oceanside, NY 11571, USA, E-mail: [mike.sood@gmail.com](mailto:mike.sood@gmail.com)

Received: 04 April 2022; Accepted: 05 May 2022; Published: 13 May 2022

Citation of this article: Iman, A., Park, WJ., R-Sood, M. (2022) Partially Resolving Myocardial Fibrosis Five Months Following the mRNA COVID-19 Vaccine: An MRI Based Case Report. J Heart Cardiovasc Med, 5(1): 08-16.

Copyright: © 2022 Michael R. Sood, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

**Introduction:** Myocarditis is a disease that has varying severity and its diagnosis or management can pose as a challenge to clinicians. With over 250 million people receiving the mRNA covid vaccine, there have been rare reports of myocarditis or other cardiovascular involvement.

**Case:** We report a 30-year-old healthy male who was hospitalized for chest pain 3 days after receiving the second dose of the covid-19 vaccination. He had high cardiac laboratory markers (cardiac troponin I peak of 22 ng/mL, normal <0.03 ng/mL) with dynamic ST segment elevations in the inferior and lateral leads. He had a subsequent coronary angiogram and echocardiogram that were normal with elevated inflammatory markers and hence, was diagnosed with myocarditis. He had a cardiac magnetic resonance (CMR) study approximately 8 weeks later (from the date of his second covid vaccine dose) that showed prominent mid to epicardial lateral wall fibrosis corresponding to similar ECG territory with normal T1 and T2 mapping. A repeat CMR was performed 5 months later (from the second vaccine dose) that showed persistent, though partially resolving fibrosis, despite the full resolution of all symptoms and biomarkers.

**Conclusion:** This case demonstrates acute myocarditis following the second dose of the mRNA covid-19 vaccination with evidence of persistent fibrosis on CMR 2 months later and on follow-up CMR scan 5 months from administration of the second dose of the vaccine. Furthermore, it demonstrates correlation of scar territory on CMR with initial ECG changes and lingering fibrosis despite the normalization of symptoms, and traditional work-up and surveillance methods. It provides insight into its

natural course and an insidious recovery as well as the utility of CMR in clinical management.

**Keywords:** Cardiac magnetic resonance imaging, CMR, Fibrosis, Covid Vaccine, Myocarditis

**Abbreviations:** CMR: Cardiac magnetic resonance; COVID-19: Coronavirus disease 2019; VAERS: Vaccine Adverse Event Reporting System; Tmax: Maximum recorded temperature; FEU: Fibrinogen Equivalent Unit; WBC: White Blood Cells; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ECG: Electrocardiogram; LGE: Late gadolinium enhancement

## Introduction

Myocarditis is a heterogeneous disease associated with acute or chronic inflammation of the myocardium with extremely varied clinical manifestations, ranging from mild to severe [1-5]. The association between myocarditis and other cardiovascular involvement from the covid-19 vaccines (Pfizer-BioNTech and Moderna) was notified by the US Centers for Disease Control and Prevention's safety committee on the June 23rd, 2021 [6]. As more than 250 million people have received at least one dose of COVID-19 vaccine in the United States, as of February 5th, 2022; rare reports of myocarditis have been made to the Vaccine Adverse Event Reporting System (VAERS) (I.e: Pfizer-BioNTech, Moderna) in the United States [7-10].

We report a case of an otherwise healthy young adult who presented to our hospital with acute myocarditis 3 days after receiving the second dose of the mRNA COVID-19 Vaccination. Cardiovascular Magnetic Resonance Imaging (CMR) was performed 2 months later that showed myocardial fibrosis of the lateral wall. A follow-up CMR (5 months since symptoms) showed persistent fibrosis despite the full resolution of symptoms and normalization of inflammatory and cardiac biomarkers.

## Case Report

A 30-year-old otherwise healthy male with no past medical history presented to our emergency department with substernal chest pain, **3 days after** he had received the **second dose of the mRNA COVID-19 Vaccine**. He experienced flu-like symptoms including subjective fevers (reported maximum recorded temperature or Tmax <100 degrees Fahrenheit) and general malaise shortly af-

ter vaccine administration. He woke up at 5 am with a sensation of pressure like chest pain that was substernal and associated with diaphoresis and mild nausea that prompted emergency room visit. His prior dose of the vaccine (1st dose) was several weeks earlier, and he reported a mild flu-like illness at that time, which was self-limiting. He denied shortness of breath, cough, rhinorrhea, anosmia, or sick contacts, or prior exposure to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There was no significant social history or a history of illicit drugs or alcohol use.

## Laboratory and imaging

Initial labs revealed a significant elevation in Troponin I of 15.4 ng/mL (normal range <0.03 ng/mL). D-dimer was <0.27 ug/ml Fibrinogen Equivalent Unit (FEU), normal range <0.50 ug/mL FEU). A computed tomography angiography of his pulmonary arteries with intravenous contrast was performed emergently (prior to d-dimer result and to rule out vaccine induced thrombo-embolism) that showed no evidence of pulmonary emboli, aortopathy or acute pulmonary pathology. SARS-CoV-2 polymerase chain reaction (PCR) was negative. White blood cells (WBC) were 7 (thousand per cubic milliliter) K/uL (normal range: 4.5-10.3 K/uL). Erythrocyte sedimentation rate (ESR) was 11 (millimeters per hour) mm/hr (normal range 0-15 mm/hr). C-reactive protein (CRP) was 40.86 (milligrams per liter) mg/L (normal range: < 5.1 mg/L). Repeat Troponin trended upwards and peaked at 22.3 ng/ml. Initial electrocardiogram (ECG) is listed in Figure 1, below. A repeat ECG revealed ST segment elevations in the inferior and lateral leads, Figure 2. Chest X-ray was without significant findings.

## Hospital course

The patient was initially treated as an acute coronary syndrome due to the nature of his pain, elevated cardiac enzymes, and ECG abnormalities via guideline directed management for acute coronary syndrome [11]. On the second day of hospitalization, he had undergone a coronary angiogram, which revealed no coronary artery disease. Transthoracic echocardiogram revealed no regional wall abnormalities and a left ventricular ejection fraction (EF) >55% with a normal right ventricular ejection fraction and no pericardial effusion. The patient was started on colchicine and ibuprofen with subsequent resolution of chest pain for the diagnosis of myopericarditis and subsequently discharged. The patient reported full resolution of all symptoms 3 weeks later.


Two months later (since the second dose of COVID-19 Vaccine), the patient underwent elective CMR, using General Electric Signa Artist 1.5 Tesla with scan parameters of images with field of view 36 x 32 mm, slice thickness 8 mm, 0 mm spacing, matrix 200 x 200 pixels mm, number of excitations 1. Gadolinium-enhanced

imaging was performed approximately 10 min after administration of 0.1 mmol/kg body weight of gadobutrol (Gadovist; Bayer). It revealed evidence of mid-myocardial fibrosis of the basal infero-lateral and lateral walls. There was homogenous signal intensity on T2 weighted images with normal native T1/T2 values on corresponding maps throughout the ventricle (Figure 4, a-e). The pericardium was normal in thickness without evidence of effusion or interventricular dependence.



The patient underwent follow-up CMR 3 months later (5 months since the second vaccine dose) to document resolution of his fibrosis, however, it showed persistent, though diminished, fibrotic area in the same corresponding territory as prior scan and normal T1 and T2 values on respective T1/T2 maps. The patient remained symptom free.

## Discussion

Recently published reports suggest the rare occurrence of myocarditis in the young males, with less than 106 cases per million doses








of the COVID-19 vaccine and in most instances within the first week after receiving the second dose of the COVID-19 vaccine [6]. Almost one hundred percent of them had significantly elevated cardiac troponin levels (10-fold to 400-fold the upper limits of their respective reference ranges) [2,10-12] Other recent reports suggest that prior exposure to either COVID-19 infection or the COVID-19 vaccine (1st dose) significantly increased the risk of myocarditis after the second exposure [5-13].

Due to the wide variation in the severity of illness in myocarditis, ranging from self-limiting to fulminant heart failure with cardiogenic shock and / or death, the diagnosis and surveillance of

myocarditis can be a challenge to clinicians [14,16-17]. Often it's diagnosis is made clinically based on various exposures to viral, infectious or immunization exposures [16]. Laboratory makers such as high sensitivity troponin assays as well as the evaluation of cardiac function via echocardiography are often the primary methods for its diagnosis, while myocardial biopsy is reserved for life threatening cases and is considered the gold standard. However, even with biopsy, there is not one widespread sole method for diagnosing myocarditis and often the laboratory, imaging and clinical history together are used [12-17]. Furthermore, despite the high prevalence of elevated laboratory inflammatory or biomarkers in acute phases, the utility in using such markers to aid




**Figure 4 (a-c):** Follow-up CMR 5 months from symptoms with partial resolution of infero-lateral and lateral fibrosis with LGE (blue arrows) on PSIR short axis view (a); 3-chamber view gradient echo (b); gradient echo short axis view (c); T1 map with uniform signal at 1000 milliseconds (d); T2 weighted image with fat saturation and homogenous signal intensity in short axis view (e).

in the assessment of chronic phases or resolution is not well established.

CMR is the gold standard in detecting cardiac anatomy and ventricular function and has been shown to have high accuracy for the diagnosis and surveillance of myocarditis [20,26]. Patients with acute myocarditis have been found to have significantly lower ejection fraction and wall motion abnormalities in comparison to echocardiography [27]. The tissue based CMR markers, such as T2-weighted ratio, early gadolinium enhancement, and late gadolinium enhancement (LGE) are used by The Lake Louise criteria, which is currently the recommended diagnostic criteria [18,19]. LGE effectively identifies the areas of damage of myocardium with high affinity [9]. The damage in the myocardium can be visualized after intravenous injection of gadolinium, which is retained for prolonged period in the damaged areas, such as scarred, fibrosed or edematous areas of the myocardium, due to different wash-in and wash-out kinetics [4,9]. This test has a reported sensitivity of 100% and specificity of 90% [4,9].

Further advances in CMR have used T1 and T2 mapping with or without extracellular volume assessment and have shown to augment the diagnostic utility of CMR in myocarditis [18,20-22]. Myocardial ischemia, infarction or edema in focal areas of the myocardium can be detected by T1 or T2 weighted sequences with mapping [20]. T1 maps can detect edema in infarction with a high sensitivity and specificity [20]. On the other hand, T2-weighted sequences with mapping can assess myocardial edema in ischemic and other non-ischemic heart diseases, such as myocarditis, Takotsubo cardiomyopathy, and transplant rejection [20,23]. Some studies suggest that myocardial abnormalities can be detected to a greater extent along with the differentiation of the convalescent stages in myocarditis with native T1 mapping when used in conjunction with T2-weighted imaging and LGE [21]. Other studies have suggested that acute myocarditis can be differentiated from recent heart failure by myocardial T2 values [21]. A summary of imaging techniques used to assess myocarditis is below, Figure 6, borrowed from Karamitos, ED, et al, [24].





Our findings demonstrate multiple parameters that confirm myocarditis while demonstrating an insidious course. Our patient had significant ECG changes, elevated cardiac biomarkers (without evidence of coronary artery disease) in conjunction with recent vaccine exposure 3 days prior, and elevated inflammatory markers (CRP). He was hence diagnosed and treated for myocarditis. Due to his chest pain and nonspecific ECG changes, we treated him with non-steroidal anti-inflammatory medications overlapping with the clinical treatment of pericarditis. We were also unaware at the time of treatment of the correspondence of his infero-lateral ECG changes with the same fibrotic territory later documented on CMR. Despite initial elevated cardiac markers, he had normal left ventricular function on echocardiography without wall motion abnormalities or effusion and resolved symptoms with clinical stability and down trending biomarkers. Hence, his CMR was scheduled electively but was notably delayed due to conflicts. Due to his clinical stability and close follow-up, we did not feel that myocardial biopsy or further pharmacotherapies were warranted.

It is noteworthy that there have been studies to suggest that viral myocarditis has a higher predominance of involving the lateral wall [25,27]. Our patient was tested negative for SARS-CoV-2 on admission and denied any prior exposure. However, it remains unclear to us if this similar fibrosis pattern seen following the vaccine administration is coincidental or related to mRNA vaccine technology. It is also of note that at the time of first CMR scan, the patient was symptom free and there was no concurrent myocardial edema on T2 weighted imaging or abnormalities on T1 or T2 mapping, respectively, at the time of his first scan. Due to the normal T1 and T2 weighted images, as well as T1 and T2 mapping, we suspected that his myocarditis was subacute or resolving at the time of his first scan. We, hence, recommended close follow-up, Holter monitoring for arrhythmias and limitation of intense aerobic activities until further resolution of his fibrosis was demonstrated. We chose to repeat CMR scan in 3 months, however, this strategy was also not well defined in current guidelines and was at the provider discretion (similar to heavy aerobic exercise limitation). To our surprise, his repeat CMR showed persistent though resolving fibrosis despite remaining symptom free with the normalization of all cardiac and inflammatory biomarkers. To the

best of our knowledge, this is the only CMR based report that has documented the lengthy timing of resolving fibrosis in the setting of covid-19 vaccine related myocarditis. Overall, it correlates with a benign clinical course and sheds information on an insidious and slow resolution of myocardial fibrosis that may persist and lag in the time after improvement of symptoms and other biomarkers. Further and larger studies are suggested.

## Conclusion

This case demonstrates persistent myocardial fibrosis on CMR 2 and 5 months from illness after the second dose of the mRNA vaccine. The fibrosis pattern has notably diminished in size on follow-up scan, however, remains persistent long after the normalization of all inflammatory and cardiac biomarkers, and symptoms. The location of the fibrosis on CMR also correlates with ECG territorial involvement and provides insight into the natural course and insidious recovery of covid-19 vaccine related myocardial involvement as well as the utility of CMR.

## Declarations

Ethical approval was not applicable for this paper.

Consent for publication was obtained. All images and data have been kept anonymous.

Availability of data and materials is available upon request.

All authors report no competing interests, funding or financial disclosures.

## Author Contributions

AFM Ashik Imran is a primary author.

Won Jun Park is an additional author and contributor.

Michael Sood is an additional primary author and mentor.

## Acknowledgments

We would like to acknowledge the Division of Cardiology and Department of Radiology at Mount Sinai South Nassau, NY, USA

## References

1. Olmulder, MA., van Es, J., Galjee, MA. (2009) The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. *Neth Heart J*, 17(12): 481-486.
2. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., et al. Myocarditis Following Immunization with mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol*, 6(10): 1202-1206.
3. Wise, J. (2021) Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? *BMJ*, 373: n1635.
4. Tschöpe, C., Ammirati, E., Bozkurt, B., Caforio, AL., Cooper, LT., Felix, LT., et al. (2021) Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. *Nat Rev Cardiol*, 18(3): 169-193.
5. Caforio, AL., Mahon, NJ., Tona, F., McKenna, WJ. (2002) Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. *Eur J Heart Fail*, 4(4): 411-417.
6. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination | CDC
7. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination | JAMA Cardiology | JAMA Network
8. Oster, ME., Shay, DK., Su, JR., Gee, J., Creech, CB., Broder, KR., et al. (2022) Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *JAMA*, 327(4): 331-340.
9. Mahrholdt, H., Goedecke, C., Wagner, A., Meinhardt, G., Athanasiadis, A., Vogelsberg, H., et al. (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. *Circulation*, 109(10):1250-1258.
10. Shay, DK., Shimabukuro, TT., DeStefano, F. (2021) Myocarditis Occurring After Immunization with mRNA-Based COVID-19 Vaccines. *JAMA Cardiol*, 6(10): 1115-1117.
11. Amsterdam, E., Wenger, N., Brindis, R., Casey Jr, DE., Ganiats, GT., Holmes, DR., et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am CollCardiol*, 64(24): e139-e228.
12. Kim, HW., Jenista, ER., Wendell, DC., Azevedo, CF., Campbell, MJ., Darty, SN., et al. (2021) Patients with Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol*, 6(10): 1196-1201.
13. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., et al. (2021) Myocarditis following COVID-19 mRNA vaccination. *Vaccine*, 39(29): 3790-3793.
14. Hazebroek, MR., Everaerts, K., Heymans, S. (2014) Diagnostic approach of myocarditis: strike the golden mean. *Neth Heart J*, 22(2): 80-84.
15. Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O'Connell, J., et al. (1996) Report of the 1995 world health organization/international society and federation of cardiology task force on the definition and classification of cardiomyopathies. *Circulation*, 93(5): 841-842.
16. Kindermann, I., Barth, C., Mahfoud, F., Ukena, C., Lenski, M., Yilmaz, A., et al. (2012) Update on myocarditis. *J Am Coll Cardiol*, 59(9): 779-792.
17. Baughman, KL. (2006) Diagnosis of myocarditis: death of Dallas criteria. *Circulation*, 113(4): 593-595.
18. Pan, JA., Lee, YJ., Salerno, M. (2018) Diagnostic Performance of Extracellular Volume, Native T1, and T2 Mapping Versus Lake Louise Criteria by Cardiac Magnetic Resonance for Detection of Acute Myocarditis: A



- Meta-Analysis. *Circ Cardiovasc Imaging*, 11(7): e007598.
19. Friedrich, MG., Sechtem, U., Schulz-Menger, J., Holmvang, G., Alakija, P., Cooper, LT., et al. (2009) International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. *J Am Coll Cardiol*, 53(17): 1475-1487.
  20. h-Ici, DO., Jeuthe, S., Al-Wakeel, N., Berger, F., Kuehne, T., Kozerke, S., et al. (2014) T1 mapping in ischaemic heart disease. *European Heart Journal - Cardiovascular Imaging*, 15(6): 597-602.
  21. Kim, PK., Hong, YJ., Im, DJ., Suh, YJ., Park, CH., Kim, JY., et al. (2017) Myocardial T1 and T2 Mapping: Techniques and Clinical Applications. *Korean J Radiol*, 18(1): 113-131.
  22. Messroghli, DR., Moon, JC., Ferreira, VM., Grosse-Wortmann, L., He, T., Kellman, P., et al. (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2\* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). *J Cardiovasc Magn Reson*, 19(1): 75.
  23. Montant, P., Sigovan, M., Revel, D., Douek, P. (2015) MR imaging assessment of myocardial edema with T2 mapping. *Diagn Interv Imaging*, 96(9): 885-890.
  24. Karamitsos, TD., Arvanitaki, A., Karvounis, H., Neubauer, S., Ferreira, VM. (2020) Myocardial Tissue Characterization and Fibrosis by Imaging. *JACC Cardiovasc Imaging*, 13(5): 1221-1234.
  25. Yelgec, NS., Dymarkowski, S., Ganame, J., Bogaert, J. (2007) Value of MRI in patients with a clinical suspicion of acute myocarditis. *Eur Radiol*, 17(9): 2211-2217.
  26. Law, YM., Lal, AK., Chen, S., Čiháková, D., Cooper, LT., Jr, Deshpande, S., et al. (2021) American Heart Association Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young and Stroke Council. Diagnosis and Management of Myocarditis in Children: A Scientific Statement From the American Heart Association. *Circulation*, 144(6): e123-e135.
  27. Yelgec, NS., Dymarkowski, S., Ganame, J., Bogaert, J. (2007) Value of MRI in patients with a clinical suspicion of acute myocarditis. *Eur Radiol*, 17(9): 2211-2217.